---
title: "Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284619759.md"
description: "Needham analyst David Saxon has maintained a Hold rating on Bausch + Lomb (BLCO) stock due to strong Q1 performance, including revenue and EBITDA exceeding expectations, and positive momentum in the pharmaceuticals division. However, uncertainty surrounding the company's planned spin-off from Bausch Health Companies tempers this outlook. Barclays also reiterated a Hold rating with a $20.00 price target."
datetime: "2026-04-29T17:45:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284619759.md)
  - [en](https://longbridge.com/en/news/284619759.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284619759.md)
---

# Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating

Needham analyst David Saxon has maintained their neutral stance on BLCO stock, giving a Hold rating on April 23.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

David Saxon has given his Hold rating due to a combination of factors tied to both operating performance and corporate structure. He acknowledges that first-quarter 2026 revenue exceeded expectations, helped in part by favorable foreign exchange, and that EBITDA also surpassed consensus. He also notes that the pharmaceuticals division outperformed, with Xiidra demonstrating stronger-than-anticipated momentum and now projected to deliver low double-digit growth instead of the previously assumed mid-single-digit pace.

At the same time, Saxon highlights that year-over-year margin expansion, supported by disciplined SG&A spending, points to improving efficiency across the business. Despite this constructive start to the year, he keeps a neutral stance because there is still insufficient clarity around Bausch + Lomb’s planned separation from its parent, Bausch Health Companies. This structural uncertainty tempers the otherwise positive fundamentals, leading him to maintain a Hold rather than move to a more decisive rating.

In another report released on April 23, Barclays also reiterated a Hold rating on the stock with a $20.00 price target.

### Related Stocks

- [BLCO.US](https://longbridge.com/en/quote/BLCO.US.md)
- [BHC.US](https://longbridge.com/en/quote/BHC.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [Q2 EPS Estimate for Bausch Health Cos Boosted by Analyst](https://longbridge.com/en/news/287048618.md)
- [Bausch Health Announces 2026 Annual Meeting of Shareholder Results | BHC Stock News](https://longbridge.com/en/news/286961143.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md)